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Abstract The crucial role of chemokines in the initiation
and progression of atherosclerosis has been widely recog-
nized. Through essential functions in leukocyte
recruitment, chemokines govern the infiltration with
mononuclear cells and macrophage accumulation in
atherosclerotic lesions. Beyond recruitment, chemokines
also provide homeostatic functions supporting cell survival
and mediating the mobilization and homing of progenitor
cells. As a new regulatory layer, several microRNAs
(miRNAs) have been found to modulate the function of
endothelial cells (ECs), smooth muscle cells and macro-
phages by controlling the expression levels of chemokines
and thereby affecting different stages in the progression of
atherosclerosis. For instance, the expression of CXCL1 can
be down-regulated by miR-181b, which inhibits nuclear
factor-jB activation in atherosclerotic endothelium, thus
attenuating the adhesive properties of ECs and exerting
early atheroprotective effects. Conversely, CXCL12 ex-
pression can be induced by miR-126 in ECs through an
auto-amplifying feedback loop to facilitate endothelial re-
generation, thus limiting atherosclerosis and mediating
plaque stabilization. In contrast, miR-155 plays a pro-
atherogenic role by promoting the expression of CCL2 in
M1-type macrophages, thereby enhancing vascular
inflammation. Herein, we will review novel aspects of
chemokines and their regulation by miRNAs during
atherogenesis. Understanding the complex cross-talk of
miRNAs controlling chemokine expression may open
novel therapeutic options to treat atherosclerosis.
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Introduction
Chemokines are small chemotactic cytokines that play a
crucial role in the trafficking of leukocytes by activating
seven-transmembrane-domain G protein-coupled receptors
(GPCRs) [1]. Studies using mouse models with genetic
alteration in the chemokine-receptor system have high-
lighted a pivotal role of specific chemokine axes during
different stages of atherosclerosis. Besides the structural
classification based on their amino acid sequence,
chemokines are grouped according to their function in
homeostatic and inflammatory chemokines [2]. Mi-
croRNAs (miRNAs) comprise a family of non-coding
RNAs with a length of 22 nucleotides that act as post-
transcriptional and cell type-specific repressors of gene
expression [3, 4]. By regulating the expression of
chemokines, miRNAs control various cellular processes
implicated in atherosclerosis. The miRNA-mediated
regulation of chemokines varies considerably between in-
dividual chemokines, which might allow an alternative
classification system of chemokines. In the first part of the
review, we will focus on chemokines and their role in
atherosclerosis. In the following part, we will discuss
miRNAs that control the expression of chemokines during
different stages of atherosclerosis.
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Chemokines and chemokine receptors
Chemokines share a very similar tertiary structure, known as
the typical chemokine fold, which is characterized by four
cysteine residues that form two disulfide bridges [2]. At
present, approximately 50 chemokines and more than 20
receptors have been identified in humans. Chemokines are
classified into four families (CC, CXC, CX3C, and C motif
chemokine) according to the configuration of the first two
N-terminal cysteine residues [2]. Some chemokines can
share several chemokine receptors within their families and
vice versa various chemokine receptors can be activated by
multiple chemokine ligands, as has been extensively re-
viewed and summarized in recent updates on the chemokine
and chemokine-receptor superfamilies [5, 6]. In contrast,
some receptor–ligand interactions are specific and mono-
gamous such as CX3C motif chemokine 1 (CX3CL1) and its
receptor CX3C chemokine receptor (CX3CR1) or CXCL16
and CXCR6. Almost all chemokines are secreted as soluble
molecules except CX3CL1 and CXCL16, which are syn-
thesized as transmembrane proteins and only released in a
soluble form upon cleavage by metalloproteases [2].
Most chemokines can aggregate into oligomers, mainly
forming homodimers, which can be divided into two
classes. Whereas CC chemokines associate to elongated
dimers through their N-termini, CXC chemokines dimerize
to a globular quaternary structure [2]. In addition,
chemokines form also heterodimers, as it is shown for
CCL5 and CXCL4. Thereby, CXCL4 promotes the CCL5-
mediated monocyte arrest on the endothelium [7, 8].
However, the activation of receptor occurs in the
monomeric form at least in the context of cell migration.
Studies with chemokine mutants that are unable to dimer-
ize show that monomeric CCL2, CCL4, CCL5, CXCL1,
and CXCL8 bind sufficiently to their receptors and induce
cell migration in vitro [9–11]. In contrast, non-dissociating
dimers of CXCL1 and CXCL8 can efficiently bind and
activate CXCR2 but not CXCR1 [12, 13]. Although
oligomerization is not required for receptor activation, it is
essential for the function of some chemokines [9, 10].
Oligomerization may be important for the bridging pre-
sentation of chemokines bound to glycosaminoglycans
(GAGs) to their receptor, since monomeric forms of CCL5
do not bind to heparin nor activate cell arrest [14–16]. In
turn, GAGs can facilitate the oligomerization of
chemokines, indicating that oligomerization and GAGs are
closely linked [17]. Through GAG binding, chemokines
may also form haptotactic gradients for recruitment of
leukocytes. Blocking oligomerization and GAG binding of
CCL5 inhibit leukocyte recruitment into atherosclerotic
lesions [18], while CCL5 aggregation and binding to GAGs
has been implicated in CCL5-induced apoptosis [19].
Homeostatic chemokines are constitutively expressed
and navigate basal leukocyte trafficking during develop-
mental processes, hematopoiesis or immune surveillance
[6]. For instance, the CXCL12–CXCR4 axis exerts pivotal
homeostatic function by mediating the homing and reten-
tion of hematopoietic stem and progenitor cells in the bone
marrow [20]. In contrast, inflammatory chemokines are
upregulated during inflammation, thus playing a crucial
role in the innate and adaptive immune response by trig-
gering leukocyte recruitment to sites of inflammation [21].
The expression of inflammatory chemokines is tightly
regulated by pro- and anti-inflammatory transcription fac-
tors such as nuclear factor-jB (NF-jB) or the anti-
inflammatory factors Kru¨ppel-like factor (KLF) 4 and 2
[22–24]. Some chemokines can be assigned to both groups
and are referred to as dual-function chemokines [21]. In
addition to leukocyte recruitment, members of the CXC
chemokines family including CXCL12 are important dur-
ing angiogenesis [25]. CXC chemokines are divided based
on the presence and absence of the glutamic acid-leucine-
arginine (ELR) motif in their N-terminus. CXC chemoki-
nes harboring an ELR motif such as CXCL1 and CXCL8
promote angiogenesis, whereas non-ELR-CXC chemoki-
nes such as CXCL4 can inhibit angiogenesis by interfering
with other chemokines or growth factor binding [25].
The expression of chemokine receptors differs consid-
erably between subtypes of leukocytes [5, 6]. Whereas
most leukocyte subsets express CXCR4, they do not ex-
press CXCR7, both of which are receptors for CXCL12
[26, 27]. The short-term regulation of chemokine receptor
expression on the cell surface occurs via chemokine-in-
duced receptor down-modulation, which is part of the
desensitization process that allows cells to adapt their re-
sponse to chemokine stimulation. Desensitization can
occur via receptor inactivation or internalization followed
by recycling or lysosomal degradation [28]. The binding of
chemokines to GPRCs (in a two site model involving the
N-loop and N-terminus of chemokines) activates hetero-
trimeric G proteins, primarily the inhibitory Gai protein.
This affects down-stream second messengers like calcium
and cyclic adenosine monophosphate, which induce the
activation of signaling pathways including NF-jB or mi-
togen-activated (MAP) kinase pathway [29]. Thereby,
chemokines can induce cellular responses such as the ac-
tivation of integrins, which mediate the adhesion of
leukocytes.
In contrast to classical GPCRs, atypical chemokine re-
ceptors (ACKR) such as Duffy antigen receptor for
chemokines (DARCs) do not activate the conventional G
protein-mediated signaling cascades due to the lack of the
intracellular G protein-binding motif but may instead sig-
nal through b-arrestin [30]. The ACKR can function as a
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scavenger by sequestering chemokines from the circulation
and shaping their local availability in tissues. The ACKR
have recently been classified in a new nomenclature [5,
30].
Functional mechanisms of chemokines
during atherosclerosis
Chemokines play an essential role during different stages
of atherosclerosis, as studied by mouse models with genetic
alteration in the chemokine-receptor system. The combined
blocking of CCL2 and the receptors CX3CR1 and CCR5
markedly attenuated bone-marrow monocytosis and re-
duced circulating monocyte numbers, which correlated
with a substantially reduced accumulation of macrophages
within atherosclerotic lesions [31]; thus, CCL2, CX3CR1,
and CCR5 appear to play an additive and independent role
during atherosclerosis, indicating that chemokines might
regulate various processes of the accumulation of mono-
cyte-derived macrophages within atherosclerotic lesions
[31].
During the initial stages of atherosclerotic plaques de-
velopment, EC dysfunction triggers an increased
expression and immobilization of CXCL1 on the cell sur-
face, thereby inducing monocyte adhesion by activating
integrins on leukocytes [32–34]. Monocytes can be divided
into at least two different functional subsets referred to as
classical or inflammatory Ly-6Chigh and non-classical or
resident Ly-6Clow monocytes, which differ in their ex-
pression of chemokine receptors, especially for CCR2 and
CX3CR1 [35]. Whereas classical monocytes express high
levels of CCR2 and low levels of CX3CR1, non-classical
monocytes are low in CCR2 and high in CX3CR1 ex-
pression [35]. During atherogenesis, primarily classical
monocytes adhere to the endothelium to contribute to le-
sion development, likely due to their increased
mobilization into the circulation during hyperlipidemia,
which is mediated by the CCL2/CCR2 axis (already under
steady state) and by the CXCL1/CXCR2 axis [31, 36, 37].
The subsequent recruitment of circulating classical mono-
cytes into the lesions is driven by the CCL5 receptors
CCR1 and CCR5 [35]. In contrast to CCL2 which might
not particularly contribute to the adhesion of monocytes,
CCL5 deposited on atherosclerotic endothelium from pla-
telet granules triggers pro-atherogenic monocyte arrest, an
effect which is enhanced by its heteromeric interaction
with CXCL4 [7, 8, 32, 38]. Adherent monocytes transmi-
grate into the subendothelial space triggered by CCL2,
where they differentiate into macrophages [32]. Besides a
de novo influx of monocytes, the local proliferation of
macrophages plays a dominant role in lesional macrophage
accumulation [39]. Beyond a role in platelet-monocyte
complex formation and recruitment [40], the CX3CL1–
CX3CR1 axis protects against apoptosis and enforces the
survival of monocytes and macrophages in the lesions, thus
exerting an important homeostatic function in atheroscle-
rosis [41]. In the intima, macrophages engulf modified
lipoproteins and accumulate cholesterol intracellular,
thereby developing into foam cells [42]. Excessive intra-
cellular lipid storage induces the inflammatory response of
macrophages characterized by the secretion of cytokines
and chemokines such as CCL2, thus promoting the ongoing
chronic inflammatory process [42, 43]. During the pro-
gression of atherosclerosis, smooth muscle cells (SMCs)
migrate from the media to the intima of arteries, where they
proliferate and secrete extracellular matrix components
such as collagen. Thereby, SMCs build up a fibrous cap,
which increases the stability of atherosclerotic lesions
against rupture [44]. Notably, silencing the CXCL12-
CXCR4 axis promotes the stability of atherosclerotic lesion
by increasing the lesional SMC accumulation, due to an
enhanced smooth muscle progenitor cell (SPC) recruitment
into the lesions [45].
Biogenesis and function of miRNAs
MicroRNAs are presumed to regulate most of the human
protein-coding genes, given that over 60 % of human
protein-coding, genes are conserved targets of miRNAs
[46]. Most of the miRNAs are processed by the RNA
polymerase II from either independent genes or located in
introns of host genes as capped and polyadenylated pri-
mary transcripts (pri-miRs) containing a stem-loop
structure [47]. The canonical miRNA maturation pathway
comprises two cleavage steps, which involve type III
RNase enzymes. In the nucleus, the microprocessor com-
plex comprising the RNase III enzyme Drosha and its co-
factor DGCR8 cleaves the pri-miRNA into a precursor
miRNA hairpin (pre-miRNA), which is transported to the
cytoplasm via exportin-5 [47]. The second RNase III en-
zyme Dicer cleaves the hairpin structure of pre-miRNAs
near their terminal loop, which gives rise to a 22nt miR:-
miR* hetero-duplex. Dicer often interacts with double-
stranded RNA-binding domain (dsRBD) proteins such as
TAR-RBD proteins in humans, although these associations
are not necessarily required for efficient Dicer-mediated
miRNA processing [47]. Subsequently, the RNA duplex
associates with argonaute proteins in an ATP-dependent
process, thereby forming the pre-RNA-induced silencing
complex (pre-RISC) [47]. During the maturation of the
RISC, the miRNA duplex unwinds and one strand remains
incorporated in the mature RISC (guide strands and miR),
whereas the other strand (passenger strand or miR*) is
released and usually degraded [47]. Strand selection does
not always follow specific rules; however, the strand with
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the less thermodynamic stability at its 50 end commonly
remains in the RISC [47]. Not only the often abundant
guide strand, but also the passenger strand can be selected
to regulate the expression levels of its target genes [48].
Besides the canonical miRNA biogenesis pathway,
miRNAs can be processed independently of Dicer or
Drosha, like miR-451 and miR-320 [47]. The guide strand
in the RISC regulates gene expression by base pairing of
the seed sequence (nucleotide 2–8 in the 50 end of the miR)
and the miR response elements (MRE), which is pre-
dominantly located in the 30 untranslated region (30 UTR)
of the target mRNA. Thereby, miRNAs inhibit gene ex-
pression by transcript destabilization or translational
repression [47]. Beyond the canonical base-pairing pattern,
miRNAs can also operate by binding to the 50 UTR or
protein-coding region of the target mRNA [49]. In addition
to protein-coding transcripts, miRNA are occasionally
found to target long-non-coding RNAs and ribosomal
RNAs, transfer RNAs or small nuclear RNAs [49]. In hu-
man cells, 18,500 miRNA–mRNA interactions have been
identified conferring a complex regulatory network [49].
Therefore, it is conceivable that the temporal and tissue-
specific expression of chemokines is also controlled by
miRNA interactions.
Notably, the number of predicted as well as ex-
perimentally validated miRNA interactions varies
considerably between individual chemokines or chemokine
receptors (Fig. 1), which might be due to the differences in
their 30 UTR length. For instance, CCL2 comprises a 30
UTR length of only 373 base pairs, which might explain
the low number of predicted miRNA-binding sites for
CCL2. Accordingly, this limited number of MREs corre-
lates with a low number of experimentally validated
miRNA interactions (Fig. 1). In contrast, the 30 UTR length
of the homeostatic chemokine CXCL12 comprises 2630
base pairs, which correlates to a high number of predicted
and validated miRNA interactions (Fig. 1). In fact, a vast
majority of all miRNA–chemokine interactions either
predicted (20 %) and validated (53 %) for chemokines are
observed for CXCL12. Whereas the number of validated
miRNA-bindings sites reveals marked differences between
individual chemokines, chemokine receptors appear to
comprise a more evenly distributed miRNA-controlled
regulation pattern, given similar numbers of predicted and
validated MREs (Fig. 1). Together with CCR7, the
CXCL12 receptor CXCR4 still featured the highest number
of validated miRNA interactions (19). Overall, the dis-
tinctive miRNA-mediated regulation patterns of
chemokines might even allow for creating an alternative
classification of chemokines, beyond previous structural
and functional categories. In the subsequent chapters, we
will focus on miRNAs that have been experimentally
identified to regulate chemokine expression during differ-
ent stages of atherosclerosis.
CXCL1/CXCR2 axis and atherogenic monocyte
arrest
The CXCR2 ligand CXCL1 is constitutively expressed in
ECs within non-Weibel–Palade bodies and rapidly released
upon stimulation with modified lipoproteins or lysophos-
phatidic acids (LPA), as part of an acute inflammatory cell
response [34, 50]. By binding to heparin sulfate proteo-
glycans, CXCL1 is immobilized at the EC surface, thereby
not only promoting the mobilization of monocytes from the
bone marrow but also their adhesion to ECs by activating
the b1-integrin VLA-4 [32, 33, 51]. In addition to the se-
cretory release, endothelial activation transcriptionally
increases the CXCL1 mRNA levels [34]. Inhibition of the
LPA-mediated CXCL1 release impairs monocyte adhesion
and atherosclerosis in apolipoprotein E-deficient mice [34].
Accordingly, the CXCL1–CXCR2 axis has been found to
promote macrophage accumulation in established
atherosclerotic lesions [52].
Disruption of miRNA biogenesis in ECs by endothelial
Dicer deletion reduced the expression of CXCL1 in the
arteries of apolipoprotein E-deficient mice, thereby at-
tenuating monocyte adhesion to early atherosclerosis-prone
endothelium [53]. TNF-a and hyperlipidemia induced the
expression of miR-103, whereas the absence of endothelial
Dicer consistently reduced miR-103 at different stages of
atherosclerosis (Hartmann et al., unpublished data). In vit-
ro, miR-103 promoted the expression and release of
endothelial CXCL1 by translational repression of KLF4
through a conserved binding site in its 30 UTR region
(Table 1; Fig. 2). The expression of CX3CL1 and CCL2
was likewise regulated by the miR-103-mediated KLF4
suppression. KLF4 limits the activation of ECs by com-
peting with NF-jB for binding to the coactivator p300. The
impaired biogenesis of miR-103 expression following en-
dothelial Dicer knock-out may contribute to reduced lesion
formation and macrophage accumulation by balancing the
functional antagonism between KLF4 and NF-jB. In ad-
dition, endothelial miR-92a can target both KLF4 and
KLF2, thereby activating NF-jB signaling and the adhe-
sion of monocytes to ECs [54, 55]. Although the effects of
miR-92a on CXCL1 have not been studied, it seems rea-
sonable to speculate that the miR-92a-mediated reduced
monocyte adhesion is regulated via CXCL1 (Fig. 2).
Notably, deficiency of KLF2 in macrophages accelerates
atherosclerosis in hypercholesterolemic mice by increasing
monocyte adhesion and macrophage infiltration into
atherosclerotic lesions [56]. The expression of CXCL1 in
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peritoneal macrophages and plasma levels of CXCL1 is
increased in mice harboring KLF2-deficient myeloid cells
[57]. Functional studies showed that miR-150 mediates the
KLF2-mediated CXCL1 suppression. However, the pre-
dicted miR-150 binding site in the 30 UTR of CXCL1
mRNA has not been experimentally validated [57].
In contrast to miR-103, the expression levels of miR-
181b are down-regulated in the aortic intima of mice
treated with TNF-a or fed a high-fat diet, thereby en-
hancing CXCL1 expression (Table 1; Fig. 2) [58, 59]. The
anti-inflammatory function of miR-181b was attributed to
the inhibition of NF-jB by targeting the transporter protein
importin-a3, which results in reduced nuclear translocation
of p65 [58]. In vitro, miR-181b attenuates the adhesion of
THP-1 cells to TNF-a stimulated ECs, most likely by re-
ducing CXCL1 [58]. Systemic delivery of miR-181b limits
NF-jB activation and inflammatory gene expression in the
aortic intima of the vessel wall of apolipoprotein E-defi-
cient mice. In addition, miR-181b overexpression reduces
atherosclerotic lesion formation and macrophage accumu-
lation in these mice by targeting importin a3 in aortic ECs
[59]. Correspondingly, miR-181b levels are reduced in the
Fig. 1 The chemokine–miRNA interactome: a classification of
chemokines according to their miRNA-regulation pattern. Black lines
are indicating experimentally validated interactions of miRNAs
within the 30 UTR region of murine chemokine or chemokine
receptor transcripts using the web tool DIANA-TarBase v7.0 [109].
Chemokines/chemokine receptors without validated miRNA interac-
tions have not been included in the interactome. The size of the
circles in orange (chemokines) or red (chemokine receptors)
corresponds to the number of predicted miRNA-binding sites in the
30 UTR of the respective transcripts. A substantial number of putative
miRNA-binding sites is predicted for CXCL12, which is in accor-
dance with a high number of experimentally validated miRNA–
CXCL12 interactions. In fact, a striking majority (53 %) of all
validated miRNA interactions among all chemokines were observed
for CXCL12 alone. In contrast, a limited number of miRNA
interactions is predicted for other chemokines such as CCL2 or
CXCL1 and for chemokine receptors, in accordance with a low
number of functionally validated miRNA-binding sites for those
transcripts
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plasma from patients with coronary artery disease. How-
ever, miR-181b does not regulate NF-jB signaling in
leukocytes based on the distinct expression pattern of im-
portin family members. In contrast to ECs, importin a5 was
predominantly expressed in leukocytes.
Moreover, the adhesive properties of ECs are regulated
by miR-712 and its human homolog miR-205 most likely
by targeting the tissue metallopeptidase inhibitor 3
(TIMP3) in ECs, thereby triggering the release of soluble
TNF-a. miR-712 increases monocyte adhesion in vitro and
Table 1 Overview of miRNA-regulated chemokines in atherosclerosis
miRNA Target Effector cell Affected chemokine Role in atherosclerosis References
miR-181b Importin-a3 ECs CXCL1 Protective [58]
miR-103 KLF4 ECs CXCL1
CCL2
Damaging Unpublished
miR-126-3p RGS16 ECs CXCL12 Protective [64]
miR-10a TAK1, b-TRC ECs CCL2 Protective [87]
miR-92a KLF2, KLF4, SOCS5 ECs CCL2
CXCL1?
Damaging [88]
miR-21 PPARa ECs CCL2 Damaging [79]
let-7g THBS1, TGFBR1, SMAD2 ECs CCL2 Protective [97]
miR-155 BCL6 Macrophages CCL2 Damaging [43]
miR-342-5p AKT1 Macrophages CCL2 (via miR-155) Damaging [102]
miR-467b LPL Macrophages CCL2 Protective [105]
miR-24 CHI3L1 Macrophages CCL2 Protective [108]
miR/miRNA microRNA, RGS16 regulator of G-protein signaling 16, TAK1 transforming growth factor b-activated kinase 1, b-TRC b-transducin
repeat-containing gene, KLF2/4 Kru¨ppel-like factor 2/4, SOCS5 suppressor of cytokine signaling 5, TLR4 toll-like receptor 4, TRAF6 TNF
receptor-associated factor 6, IRAK1/2 interleukin-1 receptor-associated kinase 1/2, PPARa peroxisome proliferator-activated receptor a, THBS1
thrombospondin 1, TGFBR1 transforming growth factor, beta receptor 1, SMAD2 SMAD family member 2, Bcl6 B-cell lymphoma 6 protein,
Akt1 v-akt murine thymoma viral oncogene homolog 1, CHI3L1 chitinase 3-like 1, LPL lipoprotein lipase
Fig. 2 miRNAs control inflammatory response in ECs. miRNAs
control the expression of inflammatory chemokines such as CCL2 and
CXCL1 predominantly indirectly by regulating the expression of
signaling molecules of the NF-jB signaling pathway. For instance,
miR-181b inhibits the NF-jB-mediated CXCL1 expression by
suppressing the expression of importin-a3, which is required for the
nuclear translocation of NF-jB. miR-103 and miR-92a targets the
NF-jB inhibitor KLF4, thereby increasing CCL2 and CXCL1
expression in ECs. In contrast, miR-21 reduces CCL2 expression by
blocking the AP-1 signaling pathway. A direct regulation of CCL2 is
reported for miR-495, which induces CCL2 mRNA degradation by
binding to its response element in the 30 UTR. Moreover, miR-126-3p
controls the expression of CXCL12, directly and indirectly via its
target RGS16. NF-jB nuclear factor-jB, CCL2 chemokine (CC
motif) ligand 2, CXCL1 chemokine (CXC motif) ligand 1, CXCL12
chemokine (CXC motif) ligand 12, CXCR4 chemokine (CXC motif)
receptor 4, KLF2/4 Kru¨ppel-like factor 2/4, SOCS1 suppressor of
cytokine signaling 1, b-TRC b-transducin repeat-containing gene,
TAK1 transforming growth factor b-activated kinase 1, TRAF6 TNF
receptor-associated factor 6, IRAK1 interleukin-1 receptor-associated
kinase 1/2, RGS16 regulator of G-protein signaling 16, SIRT1 sirtuin-
1, THBS1 thrombospondin 1, TGFBR1 transforming growth factor,
beta receptor 1, SMAD2 SMAD family member 2, PPARa per-
oxisome proliferator-activated receptor a, AP-1 activator-protein 1.
The dashed arrow indicates an indirect regulation
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silencing of miR-712 reduces atherosclerosis in mice [60].
Like for miR-92a, the effects of miR-712 on monocyte
adhesion may be indicative of a CXCL1-mediated re-
sponse; however, a causal relationship has not been
investigated in this study [60].
Importance of CXCL12/CXCR4 axis in vascular
repair
In atherosclerotic lesions, CXCL12 and its receptor
CXCR4 are highly expressed in SMCs, ECs, and macro-
phages, but not in normal vessels [61]. CXCL12 plays an
important role in homing and mobilization of progenitor
cells that express CXCR4 on their surface [62]. During
atherosclerosis, CXCR4 plays a protective role by con-
trolling neutrophil mobilization and homeostasis [63].
Moreover, silencing of CXCL12 in the vessel wall of
CXCL12-treated mice increases lesion formation with a
reduced SMC content, corroborating an anti-atherogenic
effect of the CXCL12–CXCR4 axis [45]. Notably,
CXCL12 treatment in apolipoprotein E-deficient mice
elevates CXCL12 plasma levels and promotes the tran-
scription of CXCL12 in ECs [45]. Accordingly, endothelial
CXCL12 expression is auto-amplified via a CXCR4-
mediated feedback loop unleashed by miR-126-3p, which
is delivered by endothelial apoptotic bodies (Table 1;
Fig. 2) [64]. Thereby, miR-126-3p suppresses its target
RGS16, a negative regulator of G-protein-dependent
CXCR4 signaling. The upregulation of endothelial
CXCL12 mediated by apoptotic body-derived miR-126-3p
in early atherosclerosis reduces lesion formation by di-
minishing the lesional macrophage content and increasing
SMC content in a CXCR4-dependent process [64]. Besides
the CXCL12/CXCR4 axis, endothelial microparticle-
derived miR-126-3p can also enhance endothelial repair by
increasing the VEGF signaling through down-regulation of
its target Sprouty-related EVH1 domain-containing pro-
tein, which acts as a VEGF signaling inhibitor [65].
However, the anti-atherogenic mechanisms of endothelial
CXCL12 and CXC4 remain to be further clarified. Notably,
the deficiency of endothelial CXCR4 in apolipoprotein
E-deficient mice impairs re-endothelialization and en-
dothelial progenitor cell recruitment after vascular injury,
indicating that the CXCL12–CXCR4 axis in ECs exerts an
atheroprotective role by inducing EC proliferation [66].
Interestingly, miR-126-3p can also directly target
CXCL12 through a canonical binding site in the 30 UTR
region of CXCL12 mRNA, diminishing the recruitment of
angiogenic progenitor cells to ischemic tissue [67]. The
Fig. 3 miRNA-mediated CCL2 expression in macrophages. The
expression of CCL2 is induced by the miR-155-mediated suppression
of the NF-jB inhibitor BCL6. miR-155 is regulated by miR-342-5p,
which targets AKT-1 and BMPR2. miR-146 acts as a negative
regulator to reduce the CCL2 expression by targeting TLR4.
Moreover, CCL2 expression is triggered by the expression of CHI3L1
and LPL, which is negatively regulated by miR-24 and miR-467a,
respectively. KLF2 expression in macrophages reduces the expression
of CCL2 by reducing miR-150, which negatively regulates miR-124a.
miR-124a directly suppresses the expression of CCL2 via its binding
site in the 30 UTR of the CCL2 mRNA transcript. NF-jB nuclear
factor-jB, CCL2 chemokine (CC motif) ligand 2, BCL6 B-cell
lymphoma 6, AKT1 v-akt murine thymoma viral oncogene homolog
1, BMPR2 bone morphogenetic protein receptor type II, TLR4 toll-
like receptor 4, TRAF6 TNF receptor-associated factor 6, IRAK1
interleukin-1 receptor-associated kinase 1/2, CHI3L1 chitinase 3-like
1, LPL lipoprotein lipase, KLF2 Kru¨ppel-like factor 2. The dashed
arrow indicates an indirect regulation
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precursor of miR-126 forms two mature miRNAs, the
guide strand miR-126-3p and the passenger strand miR-
126-5p, which are derived from the 30 arm and 50 arm of
the precursor miRNA, respectively. Both are functional
active and target distinct or identical mRNAs. Likewise
and synergistically with miR-126-3p, the passenger strand
miR-126-5p can directly target CXCL12, thereby impair-
ing inflammatory monocyte recruitment into the tumor
stroma by reducing CCL2 expression [68]. Thus, the
mechanism of mRNA target selection seems to be strongly
dependent on the cell type and context. In fact, the inter-
action of miR-126-3p or miR-126-5p with CXCL12 does
not play a significant role in the context of atherosclerosis.
In this context, miR-126-5p rather targets delta-like 1 ho-
molog, thereby promoting EC proliferation and limiting
atherosclerosis [48].
Similar to microparticle-mediated delivery of miR-126-
3p [64], systemic application of CXCL12 improves plaque
stability as characterized by increasing SMC accumulation,
collagen content, and fibrous cap thickness; however, it
does not affect lesion size in apolipoprotein E-deficient
mice with advanced atherosclerotic lesions [45]. The in-
creased lesion stability was related to inducing the
mobilization and recruitment of bone-marrow-derived
SPCs into atherosclerotic lesions, where they can differ-
entiate into SMC-like cells [45]. Similarly, extensive
mobilization of SPCs occurs during vascular repair of in-
jured arteries triggered by increased apoptosis of medial
SMCs [69]. In response to apoptosis, LPA-induced
CXCL12 is immobilized to vessel wall adherent-platelets,
which promotes neointima formation through SPC re-
cruitment, thereby mediating the repair of the vasculature
[70–72]. Disruption of the CXCL12/CXCR4 axis after
vascular injury by CXCR4 antagonists or in CXCR4-defi-
cient bone-marrow cells limits neointima formation and
SMC accumulation by reducing SPC recruitment [71, 73,
74]. In contrast to its protective effect in ECs during
atherosclerosis, the upregulation of CXCL12 in neointimal
cells during vascular repair accelerates neointima forma-
tion, indicating context- and cell type-specific roles for the
CXCL12-CXCR4 axis in arterial diseases.
In addition to CXCR4, CXCL12 can also bind to its
alternative receptor CXCR7. Whereas the mRNA tran-
scripts of CXCR7 are highly expressed in the carotid artery
wall, expression of CXCR7 protein is not detectable [75].
The discrepancy of CXCR7 mRNA and protein expression
pattern suggests a translational repression by miRNAs, e.g.,
via miR-430, which directly targets CXCR7 [76]. Activa-
tion of CXCR7 in apolipoprotein E-deficient mice by a
synthetic ligand lowers serum cholesterol levels under
hyperlipidemic stress by promoting the receptor-dependent
uptake of VLDL into adipose tissue. The lipid-lowering
effect of CXCR7 limits atherosclerotic lesion formation by
decreasing macrophage accumulation [75].
Role of the CCL2/CCR2 axis in ECs
and macrophages
The implication of chemokines in the pathogenesis of
atherogenesis has been shown first for CCL2 and its re-
ceptor CCR2. Macrophages and ECs are a major source for
CCL2 in human atherosclerotic lesions, whereas normal
arteries do not express CCL2 [77, 78]. Stimuli such as
hyperlipidemia, disturbed flow or angiotensin II induce the
expression of CCL2 during atherosclerosis [79–81]. CCR2
is highly expressed on classical monocytes compared to
non-classical monocytes, thereby defining the pro-inflam-
matory monocyte subtype [35].
Deficiency of CCL2 or CCR2 in apolipoprotein E-defi-
cient mice or low-density lipoprotein (LDL) receptor-
deficient mice attenuates the formation of atherosclerotic
and neointimal lesions, reducing lesional macrophage
content [82–84]. Accordingly, local overexpression of
CCL2 at the vessel wall in combination with hyperlipi-
demia accelerates atherosclerosis by promoting the
infiltration of macrophages into atherosclerotic lesions
[85]. In contrast to CXCL1, which mediates monocyte
adhesion by immobilization at the cell surface, CCL2 pri-
marily contributes to the transmigration of adherent
monocytes to the subendothelial space [32, 33]. Moreover,
CCR2 deficiency in mice revealed an essential role for the
CCL2/CCR2 axis in the mobilization of classical mono-
cytes from the bone marrow to sites of inflammation, which
reduces the number of circulating monocytes [37, 86].
Although the number of circulating monocytes correlates
with the development of atherosclerotic plaques and with
the content of monocytes/macrophages in the lesions [36],
the causal relationship between CCL2-mediated monocy-
tosis and accelerated atherosclerosis warrants further
clarification.
Control of CCL2 expression by miRNAs in ECs
Disturbed shear stress promotes the expression of CCL2 in
ECs by suppressing miR-10a [87]. Inhibition of endothelial
miR-10a activates NF-jB signaling by restoration of b-
transducin repeat-containing gene (b-TRC) and trans-
forming growth factor b-activated kinase 1 (TAK1), both
of which promote NF-jB activity (Table 1; Fig. 2). TAK1
directly phosphorylates and activates the IkB kinase b,
which phosphorylates the inhibitor protein IkBa to trigger
ubiquitination and proteasomal degradation through a
complex including b-TRC. Thus, both miR-10a targets
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induce the nuclear translocation of p65. Moreover, dis-
turbed flow in combination with oxidized LDL increases
the release of endothelial CCL2 by suppressing miR-92a
expression levels in a STAT3-dependent manner [54]. By
directly targeting KLF2 and KLF4, miR-92a reduces NF-
jB-mediated CCL2 release [55, 88, 89]. In addition, CCL2
expression is attenuated by miR-92a-mediated repression
of the target suppressor of cytokine signaling 5 (SOCS5),
limiting endothelial inflammation (Table 1; Fig. 2).
Although the functional relevance is still unknown, SOCS5
reduces the activation of the JAK-STAT pathway in ECs
[90]. Notably, inhibition of miR-92a by antagomiR treat-
ment reduces atherosclerotic lesion formation at the aortic
arch in LDL receptor-knock-out mice. This is associated
with lower lesional macrophage accumulation but in-
creased collagen content, indicating that miR-92a promotes
a more stable plaque phenotype [54]. Moreover, miR-92a
suppresses endothelial proliferation after vascular injury,
thereby disturbing endothelial repair. In atherosclerosis,
insufficient EC proliferation accelerates the disease pro-
gression [48]. Notably, CCL2 inhibits EC proliferation
in vitro under the regulation of miR-495, indicating an
alternative pro-atherogenic role for CCL2 in ECs beyond
mediating leukocyte recruitment [91] and triggering EC
migration for endothelial wound repair [92].
Notably, myeloid-specific deficiency of KLF2 in mice
increases the expression of CCL2, likely by reducing miR-
150 expression, which negatively regulates miR-124a tar-
geting CCL2 (Fig. 3) [57, 93]. Accordingly, reduced miR-
150 levels have been found to enhance the monocyte mo-
bilization from the bone marrow [94]. Although the miR-
150 effect in this study has been attributed to its target
CXCR4, it is likely to additionally involve a CCL2-medi-
ated response.
The induction of CCL2 by interleukin-1b (IL-1b)
stimulation simultaneously elevates the expression of en-
dothelial miR-146a/b, which targets TNF receptor-
associated factor 6 (TRAF6) and IL-1 receptor-associated
kinase (IRAK) 1/2 (Table 1; Fig. 2) [95]. TRAF6 and
IRAK1/2 are adaptor proteins mediating IL-1b signaling
pathways. Thereby, miR-146a/b functions as a negative
regulator to restrain EC inflammation by repressing NF-jB
activation as well as MAPK and activator-protein 1 (AP-1)
pathways. In addition, miR-146 suppresses the RNA-
binding protein HuR, which represses KLF2 as a tran-
scriptional activator of eNOS. Treatment of miR-146
knock-out mice with IL-1b enhances CCL2 expression,
likely due to a defect in the anti-inflammatory feedback
loop, thereby inducing vascular inflammation [95].
In contrast, miR-21 sustains the oscillatory shear stress
(OSS)-mediated CCL2 expression in ECs [79]. miR-21
targets the 30 UTR of PPARa mRNA, leading to its
translational suppression and activation of AP-1 signaling.
Moreover, AP-1 promotes the OSS-induced expression of
miR-21 and inflammatory activation, thus constituting a
positive feedback loop, by which miR-21 is auto-amplified
(Table 1; Fig. 2) [79]. Like miR-21, miR-34 acts as a
regulator of OSS-mediated CCL2 expression by suppress-
ing the NF-jB inhibitor sirtuin-1 in ECs [96]. Similarly,
sirtuin-1 expression levels are indirectly increased by let-
7g, thereby preventing endothelial senescence [97].
Moreover, let-7g diminishes CCL2 expression in ECs and
monocyte adhesion by targeting three genes of the trans-
forming growth factor (TGF)-b signaling pathway,
thrombospondin 1, TGF-b receptor 1, and SMAD family
member 2. Overexpression of let-7g prevents monocyte
infiltration and CCL2 expression in carotid arteries of
apolipoprotein E-deficient mice, whereas inhibition of let-
7g using let-7g sponge plasmids increases macrophage
accumulation (Fig. 2) [97]. Besides disturbed flow, an-
giotensin-II promotes CCL2 expression in ECs by
activating the transcription factor Ets-1 [98]. Overexpres-
sion of miR-155 and miR-221/222 in ECs decreases
angiotensin-II-induced CCL2 expression and T cell adhe-
sion to ECs by targeting Ets-1 (Fig. 2) [99]. However, the
causal relationship between CCL2 and monocyte adhesion
has not been addressed in these studies.
Control of CCL2 expression by miRNAs
in macrophages
After transmigration into the intima, monocytes differen-
tiate into macrophages, which further propagate
inflammation by secreting CCL2. The expression of CCL2
in inflammatory macrophages is driven by miR-155, which
is upregulated in macrophages of atherosclerotic lesions
(Table 1; Fig. 3) [43]. miR-155 represses the expression of
B-cell lymphoma 6 (Bcl6), a transcription factor attenuat-
ing NF-jB activation. Bcl6 maintains macrophage
quiescence by transcriptional repression via histone
deacetylation of enhancer regions from inflammatory genes
[100]. Deficiency of Bcl6 in bone-marrow cells of LDL
receptor-deficient mice substantially promotes atheroscle-
rosis by increasing CCL2 expression [101]. Accordingly,
apolipoprotein E-deficient mice harboring miR-155 knock-
out bone marrow show reduced atherosclerotic lesion for-
mation and macrophage content associated with Bcl6-
mediated CCL2 suppression. miR-342-5p enhances the
expression of miR-155 during the progression of
atherosclerosis by suppressing the target v-akt murine
thymoma viral oncogene homolog 1, which acts as an in-
hibitor of miR-155 [102]. Silencing of miR-342-5p in
apolipoprotein E-deficient mice by locked nucleic acid
(LNA) antisense oligonucleotides reduces macrophage
accumulation, lesion formation as well as miR-155 and
pro-inflammatory cytokine expression, indicating a miR-
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155-mediated inflammatory role of miR-342-5p (Table 1;
Fig. 3) [102].
Whereas miR-155 primarily enhances CCL2 expression
in macrophages, miR-146 acts as a negative regulator to
restrain NF-jB-mediated CCL2 expression by targeting
toll-like receptor 4 (TLR4) [103]. Notably, deficiency of
TLR4 in apolipoprotein E-deficient mice is associated with
lower CCL2 serum levels, reduced atherosclerosis and
macrophage infiltration [104]. Likewise, miR-467b in
macrophages protects apolipoprotein E-deficient mice from
atherosclerosis, likely through decreasing both plasma and
lesional CCL2 levels, and through suppression of lipopro-
tein lipase (Fig. 3) [105]. Moreover, the abundant
expression and secretion of chitinase 3-like 1 (CHI3L1) at
early stages of atherosclerosis triggers CCL2 expression in
macrophages via activation of MAPK and NF-jB path-
ways [106]. CHI3L1 levels are elevated in patients with
coronary artery disease and correlate with disease pro-
gression [107]. miR-24 negatively regulates the expression
of CHI3L1, indicating an anti-inflammatory role of miR-
24. Accordingly, inhibition of miR-24 using LNA
oligonucleotides accelerates the atherosclerotic lesion for-
mation and macrophage accumulation; however, it is not
known, whether the atheroprotective effect of miR-24 is
CCL2-dependent (Table 1; Fig. 3) [108].
Conclusions
Over the recent years, increasing evidence has highlighted
the crucial role for miRNAs as regulators of chemokines to
modulate and control inflammatory processes during the
initiation and progression of atherosclerosis. Overall, it is
remarkable that miRNAs appear to regulate chemokines
primarily through an indirect regulation of pro- or anti-
inflammatory transcription factors, rather than directly via
miRNA-binding sites in their mRNA transcripts. This
might be due to the comparably short length of the 30 UTR
for chemokines, with CXCL12 representing one notable
exception. It is conceivable that the ubiquitously important
roles of CXCL12 in homeostasis versus disease require an
elaborate, cell- and context-specific regulatory control of
its expression that can be accomplished by miRNAs. Under
conditions of inflammatory stimulation, the indirect
regulation of chemokines further reflects the ability of
miRNAs to fine-tune entire signaling cascades affecting the
expression of more than one chemokine, which results in a
more global and broad cellular response.
The treatment of inflammatory diseases by targeting the
chemokine system is a challenging field due to the high risk
of side effects such as impaired host defense against
pathogens. Therefore, the specific and partial blockade of
specific chemokine-receptor axes that are interacting
together during atherosclerosis might be a promising
therapeutic approach. Hence, context- and cell-specific
effects of miRNA-target interactions may allow selective
manipulations of the chemokine system during
atherosclerosis without immunological side effects. For
instance, current evidence suggests that the therapeutic
application of miR-181b may limit the release of CXCL1
from the vascular endothelium and thereby reducing
atherosclerosis, whereas the endothelial delivery of miR-
126-3p boosts atheropotective CXCL12 expression.
Moreover, blocking the interaction of miR-155 and its
target Bcl6 maintains macrophage quiescence by sup-
pressing CCL2 expression, which prevents the progression
of atherosclerosis. It can be envisioned that further inter-
actions of miRNAs with chemokines will emerge from
future research to allow for combined and complementary
targeting of chemokines through strategies employing
miRNA mimetics or antagoMirs.
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